CN116327860A - Compound anoectochilus roxburghii microcapsule for treating fatty liver and preparation method thereof - Google Patents
Compound anoectochilus roxburghii microcapsule for treating fatty liver and preparation method thereof Download PDFInfo
- Publication number
- CN116327860A CN116327860A CN202310458388.9A CN202310458388A CN116327860A CN 116327860 A CN116327860 A CN 116327860A CN 202310458388 A CN202310458388 A CN 202310458388A CN 116327860 A CN116327860 A CN 116327860A
- Authority
- CN
- China
- Prior art keywords
- parts
- fatty liver
- mass
- raspberry
- microcapsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 67
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 67
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 67
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 66
- 239000003094 microcapsule Substances 0.000 title claims abstract description 59
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 241000934230 Anoectochilus roxburghii Species 0.000 title abstract description 4
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 38
- 244000235659 Rubus idaeus Species 0.000 claims abstract description 38
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 38
- 239000002994 raw material Substances 0.000 claims abstract description 32
- 241000719836 Anoectochilus formosanus Species 0.000 claims abstract description 31
- 241000612166 Lysimachia Species 0.000 claims abstract description 25
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 15
- 235000005412 red sage Nutrition 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 13
- 240000001972 Gardenia jasminoides Species 0.000 claims abstract 9
- 244000111489 Gardenia augusta Species 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 36
- 239000003814 drug Substances 0.000 abstract description 29
- 210000004185 liver Anatomy 0.000 abstract description 28
- 210000004369 blood Anatomy 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 22
- 210000000952 spleen Anatomy 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 13
- 238000005728 strengthening Methods 0.000 abstract description 10
- 230000001717 pathogenic effect Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 230000001174 ascending effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 231100000283 hepatitis Toxicity 0.000 abstract description 2
- 208000006454 hepatitis Diseases 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241001571764 Lysimachia christinae Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 241000931143 Gleditsia sinensis Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009603 uroscopy Methods 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The anoectochilus roxburghii compound microcapsule for treating fatty liver and the preparation method thereof provided by the invention are combined by combining the medicine and food homology of traditional Chinese medicine and the pharmacological action of fatty liver, and can realize the effects of removing dampness and toxic materials, activating blood and removing blood stasis (eliminating evil to treat symptoms) and soothing liver and strengthening spleen (strengthening body resistance to treat root cause). The anoectochilus formosanus compound microcapsule comprises the following raw materials in parts by mass: 15 to 30 parts of lysimachia, 10 to 15 parts of raspberry, 5 to 10 parts of spina gleditsiae, 5 to 10 parts of gardenia and 15 to 30 parts of red sage root. The anoectochilus formosanus compound microcapsule has homology of medicine and food, and the traditional Chinese medicine effects of spina gleditsiae and radix salviae miltiorrhizae mainly belong to eliminating evil, and raspberry, herba lysimachiae and fructus gardeniae strengthen body resistance; the whole components are observed in sequence, and the effects of eliminating evil and strengthening body resistance are achieved; the raspberry has the effects of reducing turbid pathogen on treating fatty liver, the spina gleditsiae has the effects of eliminating fatty hepatitis substances on treating fatty liver, the gardenia has the effects of clearing liver fire and ascending liver fire on treating fatty liver, and the red sage has the effects of clearing blood stasis in fatty liver on treating fatty liver; strengthening body resistance and eliminating pathogenic factors.
Description
Technical Field
The invention belongs to the technical field of health-care foods, and particularly relates to a anoectochilus formosanus compound microcapsule for treating fatty liver and a preparation method thereof.
Background
According to the Chinese fatty liver control guideline, the prevalence of fatty liver in China reaches 12.5% -35.4%, so that the number of people suffering from fatty liver in China is over 1.2 hundred million, and the trend of the fatty liver is 2 hundred million. Fatty liver refers to a disorder caused by excessive accumulation of fat in liver cells due to various reasons, and is a common pathological change of liver, not an independent disease. Fatty liver disease is seriously threatening the health of people in China, is the second largest liver disease next to viral hepatitis, and the incidence rate is continuously rising, and the incidence age is gradually getting younger. The liver tissue of normal human contains a small amount of fat such as triglyceride, phospholipid, glycolipid, cholesterol, etc. in an amount of about 3% to 5% by weight of the liver, and can be called fatty liver if the fat accumulation in the liver is too much, exceeds 5% by weight of the liver or more than 50% of the liver cells are steatosis histologically. In clinic, western medicines for treating fatty liver are usually selected from vitamin B, lecithin, ursodeoxycholic acid and certain lipid-lowering drugs for treatment, but most western medicines have hepatorenal toxicity and are proved to be the most important part in treating fatty liver. In contrast, the traditional Chinese medicine has outstanding effect, has unique advantages from the idea of combining overall view and syndrome differentiation treatment, and has certain improvement effect on fatty liver treatment.
According to the clinical manifestations of fatty liver, traditional Chinese medicine belongs to the categories of hypochondriac pain, accumulation, turbid phlegm and the like, and pathogenesis of fatty liver is the deficiency and excess. Kidney deficiency in the liver and spleen is the principal aspect, and damp-heat, turbid phlegm and blood stasis are the principal aspect. Has hematopoietic function in embryo period, and has multiple functions of secreting bile, participating metabolism, generating blood coagulation factor, immunizing, removing toxic substances, etc. Because of spleen deficiency, food can not be transformed into essence, and phlegm turbidity is generated, which damages spleen and stomach for a long time and hinders gastrointestinal functions. Spleen energy resolving dampness, spleen and stomach qi dysfunction can stop water dampness and gather, phlegm turbidity grows, heat is transformed by accumulation, qi movement is blocked, qi stagnation and blood circulation are unsmooth, qi, blood, phlegm and turbidity mutually beat and knot, steatohepatitis and liver fibrosis are caused.
The microcapsule has the advantages of protecting from heat, moisture, oxidation and other conditions, and prolonging the storage life; has controlled or sustained release effect, and is helpful for developing new delivery mechanism; targeting to a specific site directly delivers to the desired site; flow characteristics and the like can be improved by converting the liquid into solid particles that are easier to handle, use and store. The stability and the delayed release of the bioactive components can be improved by utilizing the nano microcapsule technology, so that the activity of the bioactive components is exerted to the maximum extent. Nowadays, microcapsules are continuously expanded from the pharmaceutical field to the fields of food manufacture, biology and the like, and become a 'new sharp tool' for effectively retaining functional components.
Disclosure of Invention
The invention aims to provide a anoectochilus formosanus compound microcapsule for treating fatty liver and a preparation method thereof, which are combined by combining the medicine and food homology of traditional Chinese medicine and the pharmacological actions of the fatty liver, and can realize the effects of removing dampness and toxic materials, activating blood and removing stasis (eliminating evil to treat symptoms) and soothing liver and strengthening spleen (strengthening body resistance to treat root cause).
In order to solve the technical problems, the invention adopts the following technical scheme:
in a first aspect, the invention provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 15 to 30 parts of lysimachia, 10 to 15 parts of raspberry, 5 to 10 parts of spina gleditsiae, 5 to 10 parts of gardenia and 15 to 30 parts of red sage root.
The further improved scheme is as follows: the material comprises the following raw materials in parts by mass: 15 parts of lysimachia, 15 parts of raspberry, 5 parts of spina gleditsiae, 10 parts of gardenia and 15 parts of radix salviae miltiorrhizae.
The further improved scheme is as follows: the material comprises the following raw materials in parts by mass: 30 parts of lysimachia, 10 parts of raspberry, 10 parts of spina gleditsiae, 5 parts of gardenia and 30 parts of radix salviae miltiorrhizae.
The further improved scheme is as follows: the Chinese medicinal composition comprises, by mass, 30 parts of lysimachia, 10 parts of raspberry, 20 parts of red sage root, 10 parts of spina gleditsiae and 5 parts of cape jasmine.
The further improved scheme is as follows: the material comprises the following raw materials in parts by mass: 20 parts of lysimachia, 10 parts of raspberry, 20 parts of red sage root, 5 parts of spina gleditsiae and 5 parts of gardenia.
The further improved scheme is as follows: the material comprises the following raw materials in parts by mass: 20 parts of lysimachia, 12 parts of raspberry, 8 parts of spina gleditsiae, 7 parts of gardenia and 25 parts of radix salviae miltiorrhizae.
The further improved scheme is as follows: the material comprises the following raw materials in parts by mass: 25 parts of herba lysimachiae, 13 parts of raspberry, 7 parts of spina gleditsiae, 8 parts of gardenia and 20 parts of radix salviae miltiorrhizae.
The further improved scheme is as follows: the material comprises the following raw materials in parts by mass: 17 parts of lysimachia, 11 parts of raspberry, 9 parts of spina gleditsiae, 9 parts of gardenia and 28 parts of radix salviae miltiorrhizae.
The further improved scheme is as follows: the material comprises the following raw materials in parts by mass: 27 parts of herba lysimachiae, 14 parts of raspberry, 6 parts of spina gleditsiae, 6 parts of gardenia and 17 parts of radix salviae miltiorrhizae.
The further improved scheme is as follows: the material comprises the following raw materials in parts by mass: 23 parts of lysimachia, 15 parts of raspberry, 5 parts of spina gleditsiae, 8 parts of gardenia and 23 parts of radix salviae miltiorrhizae.
The further improved scheme is as follows: the adhesive also comprises the following raw materials in parts by mass: 12.5 parts PEG, 12.5 parts HPC and 7.5 parts NaHCO 3 。
Based on the above protocol, microcapsules can be shaped by adding 12.5 parts PEG, 12.5 parts HPC and 7.5 parts NaHCO 3.
The further improved scheme is as follows: the raw materials according to the parts by mass are as follows: 6.0 parts of PEG (polyethylene glycol), 3.0 parts of HPC (hydroxypropyl cellulose), 3.0 parts of HPMC (hydroxypropyl methylcellulose) and 3.6 parts of NaHCO 3 。
Based on the above protocol, by adding 6.0 parts PEG, 3.0 parts HPC, 3.0 parts HPMC and 3.6 parts NaHCO 3 Microcapsules may be shaped.
In a second aspect, the invention also provides a preparation method of the anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following steps:
according to the mass parts, 15 to 30 parts of lysimachia, 10 to 15 parts of raspberry, 5 to 10 parts of spina gleditsiae, 5 to 10 parts of gardenia and 15 to 30 parts of red sage root are evenly mixed and ground into powder;
adding 60% ethanol solution (50 ml) until the mixture is held by hands to form a mass, mixing the mass and the mass to form microcapsules, and drying the microcapsules in an oven at 70 ℃ for 3 hours;
adding auxiliary ingredients of 120-130 parts of PEG, 120-130 parts of HPC and 70-80 parts of NaHCO 3 。
The beneficial effects of the invention are as follows:
fatty liver belongs to feeling exogenous evil according to the theory of traditional Chinese medicine; the food has the advantages of being sweet and thick in taste, greedy and little in fatigue, or feeling damp-heat evil, causing dysfunction of liver, spleen and kidney, generating pathological products such as phlegm dampness, blood stasis and the like, stopping accumulating in the liver, affecting viscera such as spleen, kidney and stomach; the disease belongs to deficiency and excess of the root cause and is located in the liver; liver qi stagnation and abnormal evacuation, so that qi movement is blocked, the stomach is affected by the transverse adverse flow, qi diseases and blood flow are unsmooth, and the cost is reduced; liver disease transmits spleen, spleen failing to transport and retain water dampness, long-term phlegm generation leads to phlegm-dampness stagnation and internal stagnation of liver and gall and cost diseases; patients are caused by improper diet, spleen failing to transport, emotional internal injury, liver failing to reach, long-term illness, deficiency of body, qi and blood disharmony, good and excessive phlegm, blood stasis, collateral obstruction and the like; in addition, liver failing to drain qi, qi movement being obstructed, qi stagnation and blood stasis can also lead to complex condition of the disease and difficult cure.
The anoectochilus formosanus compound microcapsule disclosed by the invention; in the traditional Chinese medicine components which are food and medicine, the traditional Chinese medicine effects of spina gleditsiae and radix salviae miltiorrhizae mainly belong to eliminating pathogenic factors, and raspberry, lotus and gardenia strengthen body resistance; the whole components are observed in sequence, and the effects of eliminating evil and strengthening body resistance are achieved; the raspberry has the effects of reducing turbid pathogen on treating fatty liver, the spina gleditsiae has the effects of eliminating fatty hepatitis substances on treating fatty liver, the gardenia has the effects of clearing liver fire and ascending liver fire on treating fatty liver, and the red sage has the effects of clearing blood stasis in fatty liver on treating fatty liver; strengthening body resistance and eliminating pathogenic factors. In addition, the formula of the invention uses the ideas of traditional Chinese medicine for removing dampness and toxin, promoting blood circulation and removing blood stasis to treat fatty liver and the theory of homology of medicine and food, and on the basis of removing pathogenic factors, the invention supplements qi, thereby achieving the purposes of reducing the leakage of microscopic substances in the body, ensuring normal lifting of the body and balancing yin and yang. The microcapsule is matched, so that the stimulation of the whole component to the human body can be reduced, the long-acting repair of the long-acting release of the herba lysimachiae in the body can be realized, the problems of easy volatilization, instability and strong stimulation are overcome, and the method has good popularization and application values.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention. All other embodiments, which can be obtained by a person skilled in the art without creative efforts, are included in the protection scope of the present invention based on the embodiments of the present invention.
Embodiment one:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 15 to 30 parts of lysimachia, 10 to 15 parts of raspberry, 5 to 10 parts of spina gleditsiae, 5 to 10 parts of gardenia and 15 to 30 parts of red sage root.
Embodiment two:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 15 parts of lysimachia, 15 parts of raspberry, 5 parts of spina gleditsiae, 10 parts of gardenia and 15 parts of radix salviae miltiorrhizae.
Embodiment III:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 30 parts of lysimachia, 10 parts of raspberry, 10 parts of spina gleditsiae, 5 parts of gardenia and 30 parts of radix salviae miltiorrhizae.
Embodiment four:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 20 parts of lysimachia, 12 parts of raspberry, 8 parts of spina gleditsiae, 7 parts of gardenia and 25 parts of radix salviae miltiorrhizae.
Fifth embodiment:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 25 parts of herba lysimachiae, 13 parts of raspberry, 7 parts of spina gleditsiae, 8 parts of gardenia and 20 parts of radix salviae miltiorrhizae.
Example six:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 17 parts of lysimachia, 11 parts of raspberry, 9 parts of spina gleditsiae, 9 parts of gardenia and 28 parts of radix salviae miltiorrhizae.
Embodiment seven:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 27 parts of herba lysimachiae, 14 parts of raspberry, 6 parts of spina gleditsiae, 6 parts of gardenia and 17 parts of radix salviae miltiorrhizae.
Example eight:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 20 parts of lysimachia, 10 parts of raspberry, 20 parts of red sage root, 5 parts of spina gleditsiae and 5 parts of gardenia. Oven drying the medicine, adding adjuvant 6.0 parts of PEG, 3.0 parts of HPC, 3.0 parts of HPMC and 3.6 parts of NaHCO 3 。
Example nine:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 30 parts of lysimachia, 10 parts of raspberry, 20 parts of red sage root, 10 parts of spina gleditsiae and 5 parts of gardenia. Oven drying the medicine, adding auxiliary ingredients of 12.5 parts of PEG, 12.5 parts of HPC and 7.5 parts of NaHCO 3 。
Example ten:
the embodiment provides a anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following raw materials in parts by mass: 23 parts of lysimachia, 15 parts of raspberry, 5 parts of spina gleditsiae, 8 parts of gardenia and 23 parts of radix salviae miltiorrhizae.
On the basis of any embodiment, the preparation method further comprises the following raw materials in parts by mass: 12.5 parts PEG, 12.5 parts HPC and 7.5 parts NaHCO 3 。
Or the following raw materials in parts by mass: 6.0 parts PEG, 3.0 parts HPC, 3.0 parts HPMC and 3.6 parts NaHCO 3 。
Example eleven:
the invention also provides a preparation method of the anoectochilus formosanus compound microcapsule for treating fatty liver, which comprises the following steps:
according to the mass parts, 15 to 30 parts of lysimachia, 10 to 15 parts of raspberry, 5 to 10 parts of spina gleditsiae, 5 to 10 parts of gardenia and 15 to 30 parts of red sage root are evenly mixed and ground into powder;
adding 60% ethanol solution (50 ml) until the mixture is held by hands to form a mass, mixing the mass and the mass to form microcapsules, and drying the microcapsules in an oven at 70 ℃ for 3 hours; when the ethanol solution is added, the mixture is just held in the hands to form the block and is just tapped to be dispersed.
12.5 parts PEG, 12.5 parts HPC and 7.5 parts NaHCO were added to the adjuvant 3 。
The application method of the anoectochilus formosanus compound microcapsule prepared by the invention comprises the following steps: 100-200ml of warm water is prepared, the throat and esophagus are moistened by water, the microcapsule is put into the mouth, and then a mouth of warm water is drunk for swallowing, so that the medicine is ensured to be flushed into the stomach.
The anoectochilus formosanus compound microcapsule prepared by the invention is suitable for people: patients with mild and moderate fatty liver have symptoms of damp-heat, inappetence, nausea, abdominal distention, blood stasis, listlessness, edema, hepatomegaly, endocrine disturbance, thin and white tongue fur, thin and astringent pulse, stomatitis, skin ecchymosis, numbness of limbs, abnormal sensation of limbs, etc.
In the invention, anoectochilus formosanus belongs to an article which is not only food but also medicine. Anoectochilus roxburghii is sweet and cool in nature, enters liver meridian, lung meridian and kidney meridian, and has the functions of clearing heat and cooling blood, and removing dampness and detoxifying. Modern pharmacological researches have proved that the composition has the pharmacological effects of protecting liver, reducing blood sugar, lowering blood pressure, promoting urination and resisting tumor.
Raspberry belongs to an article which is both food and medicine. Raspberry part of taking medicine: and (5) drying the fruits. Sex taste: sweet and sour in flavor and warm in nature. Channel tropism: it enters liver, kidney and bladder meridians. Efficacy: kidney-tonifying, essence-securing, urination-reducing, liver-nourishing and vision-improving. The main indications are: can be used for treating spermatorrhea, enuresis, frequent urination, sexual impotence, premature ejaculation, dim eyesight, and dim flower. The raspberry has the effect of reducing turbid in treating fatty liver.
Spina gleditsiae belongs to an article which is not only food but also medicine. Pungent and warm in nature. Enter liver and stomach meridians. Has effects of detumescence, expelling toxin, expelling pus and killing parasites. The gleditsia sinensis thorn is pungent and warm to dispel and unblock, can quickly reach the affected part, can promote the generation of pus, can also promote the dissipation of the pus, and can shorten the course of disease. Thus, spina Gleditsiae has antibacterial, antiallergic, immunomodulating, antitumor, anticoagulant, etc. effects. Spina Gleditsiae has effect in eliminating fatty liver.
Gardenia belongs to an article which is not only food but also medicine. Zhi Zi is bitter and cold in nature and enters heart-lung triple energizer meridian. Has effects in purging pathogenic fire, cooling blood, promoting diuresis, promoting pancreas secretion, protecting liver, promoting gallbladder function, lowering blood pressure, tranquilizing, stopping bleeding, and relieving swelling. The method comprises the following steps of: "Zhi Sheng will spit, but stir-baked black will not spit, and Zhi Zi and Zhi Zi Chi Tang are fooled into each use but not spit. Gardenia has the efficacy of clearing liver fire and ascending on fatty liver.
Dan Shen is bitter in flavor and slightly cold. It enters heart and liver meridians. Has the functions of promoting blood circulation, removing blood stasis, dredging channels, relieving pain, clearing away heart-fire, relieving restlessness, cooling blood and resolving carbuncle. Compendium of materia Medica: promoting blood circulation, removing obstruction in the heart, and treating hernia. Book of changes: pathogenic qi in the heart and abdomen, borborygmus, cold and heat accumulation, break symptoms, remove obstruction, stop restlessness and fullness, and benefit qi. The Saviae Miltiorrhizae radix has effect of removing blood stasis in fatty liver.
The curative effect judgment standard classifies curative effects into 4 grades of obvious effect, effective effect, improvement and ineffective effect according to the curative effect standard for treating fatty liver of the Chinese medicine new medicine clinical research guidelines. Has obvious effect, and the symptoms and signs disappear, urine protein is negative, and the uroscopy has no red blood cells and the kidney function is normal. It is effective in eliminating symptoms, slightly repairing damaged liver cells, and promoting liver function. Fat in liver lobule is less than or equal to 20%, transaminase is in the range of 8-40u/l, bilirubin is 3.4-17.1 mp/l, blood biochemistry (serum magnesium is 0.8-1.2 mmol/l, serum potassium is 3.5-5.5 mmol/l, serum sodium is 135-145 mmol/l) uric acid (male: 210-420 mol/l) (female: 150-350 mol/l). No improvement or exacerbation of symptoms and signs and laboratory tests. Total effective rate= (effective + improvement) number of cases/total number of cases x 100%.
In order to achieve the effective technical effect, the invention is further illustrated by the following experiment:
1. toxicity test
The compound microcapsules of the lysimachia christinae hance obtained in the eighth and ninth embodiments are used as test drugs of mice, the test drugs of the mice are set to be high, medium and low doses, the administration amounts of 100 times, 50 times and 20 times of the reuse amount of the human unit body are respectively used as test groups, a normal feeding control group is additionally arranged, and after four weeks of continuous administration, the change condition of various physiological and biochemical indexes of the mice is observed.
The test results show that the compound microcapsules of the lysimachia christinae hance obtained in the eighth and ninth embodiments have no influence on the feeding amount and the growth and development of mice, have no toxic effect on liver functions of the mice, and have no obvious difference compared with the control group.
2. Application instance
60 cases of fatty liver patients were selected and the patients were randomized into two treatment groups (20 persons each) and a control group (20 persons)
Treatment group (1): 10 men and 10 women. The desmodium compound microcapsule of the embodiment 1 for strengthening spleen, eliminating dampness, soothing liver, activating blood and improving fatty liver is taken twice in the morning and evening, and is taken for four weeks.
Treatment group (2): men 9 and women 11. The compound herba lysimachiae microcapsule with the fatty liver for strengthening spleen, eliminating dampness, soothing liver, activating blood and improving is taken twice in the morning and evening for four weeks.
Control group, 10 men and 10 women. Diet, work and rest are consistent with the treatment group as much as possible. Every person takes a certain western medicine for treatment on an empty stomach in the morning and evening for four weeks
Note that: the male patient ages between 35 and 68 years and the female patient ages between 40 and 66 years.
Conclusion: as shown in the table of the figures,
the first group is the compound microcapsules of the lysimachia christinae hance prepared according to the formula of the eighth embodiment, and the compound microcapsules are ineffective for two patients, have fatty liver improvement performance of 90 percent, and have 9 obvious effects;
the second group is the compound microcapsules of the lysimachia christinae hance prepared according to the formula of the ninth embodiment, and the compound microcapsules are effective for all patients, and have 11 obvious effects, wherein the fatty liver improvement rate is up to 100%;
the third group is a western medicine for treating fatty liver, which is taken as a control group, is ineffective for 6 patients, has a kidney function improvement rate of only 70%, and only 5 patients have obvious effects.
Therefore, the compound herba lysimachiae microcapsule prepared according to the formula of the eighth embodiment and the ninth embodiment has a liver function rate reaching 95% for fatty liver patients, and has a remarkable effect.
The invention is not limited to the above-described alternative embodiments, and any person who may derive other various forms of products in the light of the present invention, however, any changes in shape or structure thereof, all falling within the technical solutions defined in the scope of the claims of the present invention, fall within the scope of protection of the present invention.
Claims (10)
1. The anoectochilus formosanus compound microcapsule for treating fatty liver is characterized by comprising the following raw materials in parts by mass: 15 to 30 parts of lysimachia, 10 to 15 parts of raspberry, 5 to 10 parts of spina gleditsiae, 5 to 10 parts of gardenia and 15 to 30 parts of red sage root.
2. The anoectochilus formosanus compound microcapsule for treating fatty liver according to claim 1, wherein the microcapsule is characterized in that: the material comprises the following raw materials in parts by mass: 15 parts of lysimachia, 15 parts of raspberry, 5 parts of spina gleditsiae, 10 parts of gardenia and 15 parts of radix salviae miltiorrhizae.
3. The anoectochilus formosanus compound microcapsule for treating fatty liver according to claim 1, wherein the microcapsule is characterized in that: the Chinese medicinal composition comprises, by mass, 30 parts of lysimachia, 10 parts of raspberry, 20 parts of red sage root, 10 parts of spina gleditsiae and 5 parts of cape jasmine.
4. The anoectochilus formosanus compound microcapsule for treating fatty liver according to claim 1, wherein the microcapsule is characterized in that: the material comprises the following raw materials in parts by mass: 20 parts of lysimachia, 10 parts of raspberry, 20 parts of red sage root, 5 parts of spina gleditsiae and 5 parts of gardenia.
5. The anoectochilus formosanus compound microcapsule for treating fatty liver according to claim 1, wherein the microcapsule is characterized in that: the material comprises the following raw materials in parts by mass: 25 parts of herba lysimachiae, 13 parts of raspberry, 7 parts of spina gleditsiae, 8 parts of gardenia and 20 parts of radix salviae miltiorrhizae.
6. The anoectochilus formosanus compound microcapsule for treating fatty liver according to claim 1, which is characterized by comprising the following raw materials in parts by mass: 17 parts of lysimachia, 11 parts of raspberry, 9 parts of spina gleditsiae, 9 parts of gardenia and 28 parts of radix salviae miltiorrhizae.
7. The anoectochilus formosanus compound microcapsule for treating fatty liver according to claim 1, which is characterized by comprising the following raw materials in parts by mass: 27 parts of herba lysimachiae, 14 parts of raspberry, 6 parts of spina gleditsiae, 6 parts of gardenia and 17 parts of radix salviae miltiorrhizae.
8. The anoectochilus formosanus compound microcapsule for treating fatty liver according to claim 1, which is characterized by further comprising the following raw materials in parts by mass: 12.5 parts PEG, 12.5 parts HPC and 7.5 parts NaHCO 3 。
9. The anoectochilus formosanus compound microcapsule for treating fatty liver according to claim 1, which is characterized by further comprising the following raw materials in parts by mass: 6.0 parts PEG, 3.0 parts HPC, 3.0 parts HPMC and 3.6 parts NaHCO 3 。
10. The preparation method of the anoectochilus formosanus compound microcapsule for treating fatty liver is characterized by comprising the following steps of:
according to the mass parts, 15 to 30 parts of lysimachia, 10 to 15 parts of raspberry, 5 to 10 parts of spina gleditsiae, 5 to 10 parts of gardenia and 15 to 30 parts of red sage root are evenly mixed and ground into powder;
adding 60% ethanol solution (50 ml) until the mixture is held by hands to form a mass, mixing the mass and the mass to form microcapsules, and drying the microcapsules in an oven at 70 ℃ for 3 hours;
12.5 parts of PEG,12.5 parts HPC and 7.5 parts NaHCO 3 。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310458388.9A CN116327860A (en) | 2023-04-26 | 2023-04-26 | Compound anoectochilus roxburghii microcapsule for treating fatty liver and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310458388.9A CN116327860A (en) | 2023-04-26 | 2023-04-26 | Compound anoectochilus roxburghii microcapsule for treating fatty liver and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116327860A true CN116327860A (en) | 2023-06-27 |
Family
ID=86893135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310458388.9A Withdrawn CN116327860A (en) | 2023-04-26 | 2023-04-26 | Compound anoectochilus roxburghii microcapsule for treating fatty liver and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116327860A (en) |
-
2023
- 2023-04-26 CN CN202310458388.9A patent/CN116327860A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690783B (en) | Chinese medicine preparation being used for the treatment of diabetes and preparation method thereof | |
| CN103463500B (en) | Medicament for treating cerebral hemorrhage | |
| CN103860958A (en) | Traditional Chinese medicinal composition for treating acne | |
| CN102100828A (en) | Medicament for treating diabetes mellitus | |
| CN103920027A (en) | Medicament for treating acute jaundice hepatitis B and preparation method thereof | |
| CN104474104A (en) | Traditional Chinese medicine composition for preventing and treating infectious rhinitis of chicken and preparation method thereof | |
| CN114748603B (en) | Pharmaceutical composition for preventing and treating new coronavirus pneumonia from changing or restoring yang and application thereof | |
| CN103071129A (en) | Chinese patent drug for curing vomit | |
| CN116327860A (en) | Compound anoectochilus roxburghii microcapsule for treating fatty liver and preparation method thereof | |
| CN1686492A (en) | Antibicrobial anti inflammatory capsule and its preparation method | |
| CN104474225B (en) | Medicine for treating viral myocarditis and preparation method | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN107260978B (en) | Traditional Chinese medicine composition for treating hypertension and preparation method and application thereof | |
| CN104606538A (en) | Traditional Chinese medicine health product for preventing and treating diabetes | |
| CN104998158A (en) | Pharmaceutical composition for treating liver cirrhosis and application thereof | |
| CN110755523B (en) | Composition for improving hyperglycemia and preparation method thereof | |
| CN103705639A (en) | Chinese medicinal preparation for treating hydrocephalus | |
| CN103845583B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of chronic hepatitis | |
| CN1151818C (en) | Diabetes treating traditional Chinese medicine | |
| CN105998781A (en) | Pharmaceutical composition for treating acute gastroenteritis | |
| CN107050395B (en) | Traditional Chinese medicine sigmoid colon instillation preparation for treating infantile exogenous fever and preparation method and application thereof | |
| CN104740478A (en) | Traditional Chinese medicine pill for emergency treatment of alcoholism and preparation method thereof | |
| CN105106884B (en) | Qi and activate blood circulation lets out turbid side | |
| CN105106590A (en) | Medicine for treating allergic rhinitis | |
| CN105213975A (en) | A kind of pharmaceutical composition and application thereof for the treatment of liver cirrhosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230627 |